TheraRadar
Clinical-Stage Companies / Optinose

Optinose

Pre-Approval PRO BETA
13
Total Trials
10
Phase 3
0
Phase 2
2
Recruiting
164
Score

Pipeline by Phase

Phase 3
10
Phase 2
Phase 1
3

Therapeutic Focus

Bilateral Nasal Polyposis Chronic Rhinosinusitis Chronic Rhinosinusitis Without Nasal Polyps Covid19 Nasal Polyposis

Clinical Trials (13)

NCT03747458 Phase 3 RECRUITING

OPN-375 Efficacy and Safety in Adolescents With Bilateral Nasal Polyps

Started: 12/31/2018

NCT06850805 Phase 3 RECRUITING

Efficacy and Safety of 186 mcg of OPN-375 Nasal Spray Twice a Day (BID) in Adolescents With Chronic Rhinosinusitis Without Nasal Polyps

Started: 7/28/2025

NCT03781804 Phase 3 COMPLETED

Study Evaluating the Efficacy and Safety of Intranasal Administration of OPN-375 in Subjects With Chronic Rhinosinusitis With or Without the Presence of Nasal Polyps

Started: 11/27/2018

NCT03960580 Phase 3 COMPLETED

Study Evaluating the Efficacy and Safety of Intranasal Administration of OPN-375 in Subjects With Chronic Rhinosinusitis Without the Presence of Nasal Polyps

Started: 6/6/2019

NCT03591068 Phase 3 COMPLETED

Efficacy & Safety of OPN-375 Adults With Bilateral Nasal Polyps Using Nasoendoscopic Video

Started: 6/7/2018

NCT01622569 Phase 3 COMPLETED

Study Evaluating the Efficacy and Safety of Intranasal Administration of 100, 200, and 400 μg of Fluticasone Propionate Twice a Day (BID) Using a Novel Bi Directional Device in Subjects With Bilateral Nasal Polyposis Followed by an 8-Week Open-Label Extension Phase to Assess Safety

Started: 11/19/2013

NCT01624662 Phase 3 COMPLETED

Efficacy and Safety Study of Intranasal Administration of 100, 200, and 400 μg of Fluticasone Propionate Using a Novel Bi-directional Device

Started: 10/30/2013

NCT01623310 Phase 3 COMPLETED

12-Month OL Intranasal Fluticasone Propionate BID Using OptiNose Device

Started: 9/1/2013

NCT01623323 Phase 3 COMPLETED

Study Evaluating the Safety of Intranasal Administration of 400 μg of Fluticasone Propionate Twice a Day (BID) Using a Novel Bi-Directional Device in Subjects With Chronic Sinusitis With or Without Nasal Polyps

Started: 9/1/2013

NCT01462812 Phase 3 COMPLETED

Safety & Efficacy of a Single Dose of Sumatriptan Powder Delivered Intranasally With the Bi-directional Device in Adults With Acute Migraine

Started: 1/1/2011

NCT05035576 Phase 1 TERMINATED

A Study to Evaluate Change in Viral Load After OPN-019 in Adults With COVID-19

Started: 9/1/2021

NCT02266927 Phase 1 COMPLETED

A Study to Compare the Bioavailability Intranasal Administration of 200 and 400 µg or 400 µg Alone of OPTINOSE™ FLUTICASONE With 440 µg of Flovent® HFA (Fluticasone Propionate) Inhalation Aerosol (Part 2)

Started: 9/1/2014

NCT01507610 Phase 1 COMPLETED

Bioavailability Study to Compare OPTINOSE SUMATRIPTAN With IMITREX® in Healthy Subjects

Started: 1/1/2012

Drug Candidates

OPN-375 Placebo OPN-019 Fluticasone Propionate Fluticasone propionate Flovent HFA OPTINOSE™ FLUTICASONE Sumatriptan
Activity Status: Active
Last Trial Started: 7/28/2025
Last Trial Ended: 5/4/2022
Trials (12 months): 1
Completed Trials: 10
Data sourced from ClinicalTrials.gov. This company has no FDA-approved drugs.